Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.

The international journal of neuropsychopharmacology - 1 Dec 2018

Alghamdi Jahad, Matou-Nasri Sabine, Alghamdi Faisal, Alghamdi Saleh, Alfadhel Majid, Padmanabhan Sandosh

Abstract excerpt

Background: Recent studies have highlighted the possible risk of neuropsychiatric adverse effects during treatment with lipid-lowering medications. However, there are still controversies that require a novel genetic-based approach to verify whether the impact of lipid-lowering drug treatment results in neuropsychiatric troubles including insomnia, depression, and neuroticism. Thus, we applied Mendelian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Depressive Disorder
Share to Ezetimibe

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Hypolipidemic Agents

Share to Neurotic Disorders

Share to Proprotein Convertase 9

Share to Sleep Initiation and Maintenance Disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 29986042
DOI: 10.1093/ijnp/pyy060
PMCID: PMC6276028

Genes

PCSK9
HMGCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.PMID 29986042Read ↗

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Exploring repositioning opportunities and side-effects of statins: a Mendelian randomization study of HMG-CoA reductase inhibition with 55 complex traitsSemantic proximity Read ↗

Genetic association of cholesterol metabolism with the risk of depression and schizophrenia.Semantic proximity Read ↗

Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia.Semantic proximity Read ↗

Association of lipid-lowering drugs with COVID-19 outcomes: A Mendelian Randomization studySemantic proximity Read ↗

Psychiatric disorders and cardiovascular diseases: A mendelian randomization studySemantic proximity Read ↗

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive FunctionSemantic proximity Read ↗

Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization studySemantic proximity Read ↗

Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization.Semantic proximity Read ↗

Investigating the potential anti-depressive mechanisms of statins: a transcriptomic and Mendelian randomization analysisSemantic proximity Read ↗

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.Semantic proximity Read ↗

Psychiatric traits and intracerebral hemorrhage: A Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.